NF‐κB/NKILA signaling modulates the anti‐cancerous effects of EZH2 inhibition

A wealth of evidence supports the broad therapeutic potential of NF‐κB and EZH2 inhibitors as adjuvants for breast cancer treatment. We contribute to this knowledge by elucidating, for the first time, unique regulatory crosstalk between EZH2, NF‐κB and the NF‐κB interacting long non‐coding RNA (NKIL...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Cell Mol Med
Hlavní autoři: Duan, Suzann, Chan, Westin K., Oman, Andrew, Basile, Dominic P., Alvira, Cristina M., Buxton, Iain L.O., Iosef, Cristiana
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6714229/
https://ncbi.nlm.nih.gov/pubmed/31282094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14500
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky